September quarter net loss widens to Rs 37.4 crore as revenue declines 2.3%
ASTEC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 2.0 pts less than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Astec LifeSciences reported results for the September 2026 quarter and first six months. Standalone operating revenue was Rs 72.02 crore, down 2.3% from Rs 73.72 crore, and net loss widened to Rs 37.40 crore from Rs 24.42 crore. Six-month revenue fell 5.6% to Rs 155.58 crore, while net loss was Rs 56.10 crore. The consolidated operating margin worsened to negative 27.5% from negative 9.1%, and the audit review found no material misstatement.
The wider loss and weaker margin may pressure the stock, though operating cash flow improved and the auditor found no material misstatement.